Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after 1977. Currently MSM.

Slides:

Advertisements

Similar presentations

HIV/ AIDS - Yemen Successes and challenges Dr. Fouzia Abdullah Gharama Programme Manager Ministry of Public Health & Population.

Advertisements

HIV/AIDS Results Monitoring and Evaluation Systems Measuring the Multi-Sector Response.

UNAIDS/WHO Working Group on Global HIV/AIDS/STI Surveillance Introduction to 2nd Generation HIV Surveillance UNAIDS/WHO Working Group on Global HIV/AIDS.

Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.

FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.

Learning and Empowerment: “Key Issues in Strategies for HIV/AIDS Prevention” March 1-5, 2004, Chiang Mai Presented by Dr. Pum Sophiny, Program Officer.

Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.

Ecological Model for HIV Risk in MSM Stage of Epidemic Individual Community Public Policy Network Level of Risks Source: Baral and Beyrer, 2006.

Where do we focus our HIV responses in Asia? Amala Reddy UNAIDS Regional Support Team – Asia Pacific Manila, November 27 th, 2009.

Dengue Transfusion Risk Model Lyle R. Petersen, MD, MPH Brad Biggerstaff, PhD Division of Vector-Borne Diseases Centers for Disease Control and Prevention.

Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:

The Safety of the Blood Supply

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Transfusion Transmission of HIV 1. Past & Current Risk Estimates of Transfusion-Transmitted HIV Infection 2. Layers of Safety in Protection of the Blood.

1 Risks and Benefits of Home-Use HIV Test Kits Richard Forshee, Ph.D. U.S. Food and Drug Administration Center for Biologics Evaluation and Research Office.

Sex work among people who inject drugs in England, Wales & Northern Ireland: Findings from a National Survey of Health Harms and Behaviours Sara Croxford,

Current standards, donor safety, and blood supply

1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.

CBER 1 Current standards, donor safety and blood supply Orieji Illoh, MD Office of Blood Research and Review Center for Biologics Evaluation and Research.

Deferral of MSM: Policy Analysis by Andrew I. Dayton.

Workshop Summary FDA Workshop on Testing for malarial Infections in Blood Donors Sanjai Kumar, Ph.D. Center for Biologics Evaluation and Research Food.

Management of Risk and Blood Availability in Donor Populations with High Prevalence of Blood Borne Pathogens Ravi Reddy IBSF Meeting 20 March 2015.

Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.

Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.

Background Donor Suitability Consultation was held in Atlanta June 26-27, 2001 To review and consult on the 1994 CDC Guidelines for Preventing Transmission.

CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Summary and Questions for the Committee Blood Products Advisory.

A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.

FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.

Stuart Michaels, Academic Research Centers, NORC Sexual Behavior & Sexual Identity among Men who have Sex with Men (MSM)

21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-

Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.

Background Recruitment strategies for organ and tissue donors are different, and although some organ donors do eventually become tissue donors, organ donors.

Parvovirus B19 NAT Screening and Infectivity Mei-ying W Yu CBER/FDA SoGAT XVI Paul Ehrlich Institut July 03, 2003.

Aristotelis Tsiakalos, MD, PhD. Prevalence of HIV infection in Greece until 2011: 7.4/ population.

1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.

Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.

FDA Workshop on Behavior-Based Donor Deferrals in the NAT Era Lister Hill Auditorium, NIH Bethesda, Maryland March 8, 2006 Summary of the Workshop Andrew.

Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.

A W O R L D B A N K P O L I C Y R E S E A R C H R E P O R T CONTEXTUAL DETERMINANTS OF HIV Findings from “Confronting AIDS” Mead Over Development Research.

Policy and Ethics – Donors Cadaveric versus Living Donors Amy Lu, MD Georgetown University David Cronin, MD, PhD University of Chicago.

THE HIV/AIDS EPIDEMIC A quick look at the global killer Carla Mollica June 2013 – MGD 120.

Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.

Hong Yang, Ph.D. Office of Biostatistics and Epidemiology FDA-Center for Biologics Evaluation & Research Transmissible Spongiform Encephalopathies Advisory.

HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.

Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Prospects for Ending the HIV Epidemic among Persons who Inject Drugs in Haiphong Vietnam Don C Des.

Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.

Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.

Allie Lyman.  Incidence and Prevalence  Risk Factors and Barriers to Prevention  Prevention  Conclusion.

Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,

Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.

Fast-Tracking Treatment to End AIDS ICASA Ambassador Deborah Birx, MD U.S. Global AIDS Coordinator November 30, 2015.

POLICIES INVOLVING STRUCTURAL INTERVENTIONS TO REDUCE RISKS ASSOCIATED WITH HIV/AIDS IN COMMUNITIES OF COLOR IN CHICAGO, ILLINOIS William Ebomoyi, Ph.D.

Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

Albert Farrugia PhD School of Surgery University of Western Australia

Presented by Karen Dosanjh Quality Director Blood Systems

Prevalence of HIV infection among blood donors at the National Blood Transfusion Centre in Bangui, Central African Republic Claudine Bekondi1a, Pulchérie.

Ad-hoc Disease Transmission Advisory Committee

The MSM and Trans Epidemic in the Caribbean

Dr. Venkatesan Chakrapani, MD

بسم الله الرحمن الرحیم.

NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:

Operations and Safety Committee

Presentation transcript:

Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after Currently MSM are deferred for MSM behavior “…even one time, since 1977…” In 1997 FDA presented to the BPAC an analysis of the potential effects of relaxing the MSM deferral policy to “1 year” or to “5 years.” Blood banking errors, poorly quantified at the time, were considered the most significant risk of changing the policy.

Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. In November of 1998, FDA hosted a workshop on Donor Suitability. The highlights of this workshop were presented to the BPAC in December of ®Widespread adoption of NAT for HCV and HIV, providing, amongst other benefits, redundancy. ®Better understanding of blood bank error rates.

Protection of the Blood Supply INFECTION POTENTIAL DONORS BLOOD SUPPLY Tests Questionnaire Undetectable Strains Blood Bank Error Test Failure Window Period Ineffective Risk Identification Test Seeking Behavior Peer Pressure Misunderstanding of Questions Self Deferral (Education)

Protection of the Blood Supply POTENTIAL DONORS BLOOD SUPPLY Tests Undetectable Strains Blood Bank Error Test Failure Window Period Prevalence Incidence

Quantitation of Errors I: How many infectious units will “get through?” Total Errors =  P x (U + E + F ) + I x (WP/365)} x Population  Errors =  P x (U + E + F ) + I x (WP/365) } x  Population

Questions for the Committee: 1. Does the BPAC recommend that Men who have Sex with other Men (MSM) be deferred from donating blood for a period of five years following MSM activity, rather than being deferred for any MSM behavior since 1977?